

AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung disease. The study showed similar...
You can purchase shares of AN2 Therapeutics (NASDAQ:ANTX) through any online brokerage.
Other companies in AN2 Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
AN2 Therapeutics has a consensus price target of $5.40.
The stock price for AN2 Therapeutics (NASDAQ: ANTX) is $3.61 last updated October 26, 2026 at 10:10 AM EDT.
There are no upcoming dividends for AN2 Therapeutics.
AN2 Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for AN2 Therapeutics.
AN2 Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas...